Prof Rad-Onc, Chair Service of Radiation Oncology CHUV UNIL Lausanne. Passion for Immunology & Oncology. EORTC former Chair Gynecology Cancer Group. HerreraLab
CHUV Lausanne
Joined May 2020
- Tweets607
- Following528
- Followers1.1K
- Likes1.5K
Dara+ADT added to definitive radiation or in the adjuvant postop RT setting in very high risk N+ prostate cancer
Fernanda G. Herrera retweeted
Happy to share scRNA-seq dataset of murine mesenteric tissue in easy-to-use format at the Single Cell Portal
shorturl.at/mgQR9
BECs, LECs, SMCs, fibroblasts, mesothelial cells from WT & Foxc2lecKO at single-cell resolution.
Original publication: science.org/doi/10.1126/scia…
Fernanda G. Herrera retweeted
Thank you very much Nicola Diny and @JCellBiol for highlighting our work on intestinal eosinophils !🙏
Spotlight: Nicola Diny @UniklinikBonn previews a study from @petrovalab et al. (hubs.la/Q04kvJwJ0) which reveals that #eosinophils drive a developmental program for postnatal intestinal remodeling and maturation. hubs.la/Q04ks9f70
#Development
1) Why do immune-excluded tumors resist immunotherapy?
T cells are there—but they can't effectively infiltrate the tumor. pubmed.ncbi.nlm.nih.gov/4199…
#RACIN tested whether #LDRT (1 Gy) could reprogram the #TME and unlock anti-tumor immunity. @DangajD
12) Our deepest gratitude goes to the patients and their families, and to all collaborators, partners, clinicians, scientists, and study teams who made #RACIN possible. 🙏Our hospital and department. @FBM_UNIL @unil @CHUVLausanne
Fernanda G. Herrera retweeted
This is so cool!!! Thanks @TheLancetOncol #radonc
Kidney SABR on the front cover of @TheLancetOncol. A well-deserved recognition for @_ShankarSiva for his work and efforts over the past 10+ years.
thelancet.com/journals/lanon…
Fernanda G. Herrera retweeted
I’m in agreement and impressed by everything you say with the exception of handing out congratulations this is definitely not a home run. I’m not even sure I would’ve done this trial.
Fernanda G. Herrera retweeted
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
Fernanda G. Herrera retweeted
I really recommend this evidence based critical analysis of PROTEUS @NEJM article (available here: nejm.org/doi/full/10.1056/NE…).
This is a big trial, but with many issues (control arm, primary endpoint, effect size...) that may not translate into meaningful patient benefit #ASCO26
#ASCO26
The PROTEUS trial results are now online...buckle up as we wait to see the full presentation. This is going to be a trial that is likely highly controversial until the full results are published.
Some may call this a homerun, others may call this the largest negative trial @ASCO 2026. Up to you to interpret!
@urotoday @EricTopol @DrChoueiri @neerajaiims @ASCO @US_FDA @NCCN @myESMO @ASTRO_org @PCF_Science @declangmurphy @mcuban